|
Name |
(-)-Globulol
|
Molecular Formula | C15H26O | |
IUPAC Name* |
(1aR,4R,4aR,7R,7aS,7bS)-1,1,4,7-tetramethyl-2,3,4a,5,6,7,7a,7b-octahydro-1aH-cyclopropa[e]azulen-4-ol
|
|
SMILES |
C[C@@H]1CC[C@@H]2[C@@H]1[C@H]3[C@H](C3(C)C)CC[C@@]2(C)O
|
|
InChI |
InChI=1S/C15H26O/c1-9-5-6-10-12(9)13-11(14(13,2)3)7-8-15(10,4)16/h9-13,16H,5-8H2,1-4H3/t9-,10-,11-,12-,13-,15-/m1/s1
|
|
InChIKey |
AYXPYQRXGNDJFU-QTPLKFIXSA-N
|
|
Synonyms |
(-)-Globulol; Globulol; 489-41-8; G66H9XM0JK; (1aR,4R,4aR,7R,7aS,7bS)-1,1,4,7-tetramethyl-2,3,4a,5,6,7,7a,7b-octahydro-1aH-cyclopropa[e]azulen-4-ol; UNII-G66H9XM0JK; NSC-152470; EINECS 207-696-7; NSC 152470; SCHEMBL60792; GLOBULOL, (-)-; CHEMBL2171207; CHEBI:167415; DTXSID801318741; 1H-CYCLOPROP(E)AZULEN-4-OL, DECAHYDRO-1,1,4,7-TETRAMETHYL-, (1AR-(1A.ALPHA.,4.ALPHA.,4A.ALPHA.,7.ALPHA.,7A.BETA.,7B.ALPHA.))-; ZINC5528095; MFCD00042615; (1AR-(1aalpha,4alpha,4aalpha,7alpha,7abeta,7balpha))-decahydro-1,1,4,7-tetramethyl-1H-cycloprop(e)azulen-4-ol; (-)-Globulol, >=98.5% (sum of enantiomers, GC); Q27278826; (1AR-(1A.ALPHA.,4.ALPHA.,4A.ALPHA.,7.ALPHA.,7A.BETA.,7B.ALPHA.))-DECAHYDRO-1,1,4,7-TETRAMETHYL-1H-CYCLOPROP(E)AZULEN-4-OL; 1H-CYCLOPROP(E)AZULEN-4-OL, DECAHYDRO-1,1,4,7-TETRAMETHYL-, (1AR,4R,4AR,7R,7AS,7BS)-
|
|
CAS | 489-41-8 | |
PubChem CID | 12304985 | |
ChEMBL ID | CHEMBL2171207 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 222.37 | ALogp: | 3.7 |
HBD: | 1 | HBA: | 1 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 20.2 | Aromatic Rings: | 3 |
Heavy Atoms: | 16 | QED Weighted: | 0.651 |
Caco-2 Permeability: | -4.563 | MDCK Permeability: | 0.00003360 |
Pgp-inhibitor: | 0.011 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.554 |
30% Bioavailability (F30%): | 0.469 |
Blood-Brain-Barrier Penetration (BBB): | 0.131 | Plasma Protein Binding (PPB): | 96.12% |
Volume Distribution (VD): | 1.286 | Fu: | 3.42% |
CYP1A2-inhibitor: | 0.567 | CYP1A2-substrate: | 0.564 |
CYP2C19-inhibitor: | 0.226 | CYP2C19-substrate: | 0.917 |
CYP2C9-inhibitor: | 0.256 | CYP2C9-substrate: | 0.467 |
CYP2D6-inhibitor: | 0.016 | CYP2D6-substrate: | 0.447 |
CYP3A4-inhibitor: | 0.102 | CYP3A4-substrate: | 0.465 |
Clearance (CL): | 8.036 | Half-life (T1/2): | 0.44 |
hERG Blockers: | 0.09 | Human Hepatotoxicity (H-HT): | 0.109 |
Drug-inuced Liver Injury (DILI): | 0.191 | AMES Toxicity: | 0.003 |
Rat Oral Acute Toxicity: | 0.124 | Maximum Recommended Daily Dose: | 0.017 |
Skin Sensitization: | 0.417 | Carcinogencity: | 0.033 |
Eye Corrosion: | 0.985 | Eye Irritation: | 0.864 |
Respiratory Toxicity: | 0.937 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003089 | 0.618 | D0N6FH | 0.375 | ||||
ENC001192 | 0.582 | D0S3WH | 0.356 | ||||
ENC003084 | 0.527 | D0Y5ZA | 0.346 | ||||
ENC002256 | 0.483 | D0U3GL | 0.316 | ||||
ENC001196 | 0.475 | D04DJN | 0.308 | ||||
ENC003088 | 0.458 | D0B4RU | 0.305 | ||||
ENC003050 | 0.443 | D00VZZ | 0.305 | ||||
ENC003624 | 0.435 | D0Z1XD | 0.300 | ||||
ENC003125 | 0.433 | D0Q6NZ | 0.298 | ||||
ENC001321 | 0.424 | D0D4JO | 0.297 |